Betting big on Gamma Delta T Cells
News 19th May 2017

GammaDelta’s Scientific Co-Founder Adrian Hayday Receives Inaugural Business of Science Leadership Award

London, UK, 19 May 2017 – GammaDelta Therapeutics, an emerging immunotherapy company exploiting the unique properties of gamma delta (γδ) T Cells, is proud to announce that its Scientific Co-Founder, Professor Adrian Hayday, has received the inaugural Business of Science Leadership Award in recognition of his outstanding contribution to the field of gamma delta T Cell drug discovery. The new UK award was created to recognise pioneering business leadership in science.

Professor Hayday, FRS, FMedSci, commented: “I am honoured to have received this award from the Business of Science community who are so committed to accelerating the movement of fundamental discoveries into people’s lives.”